Alvogen has picked up a portfolio of four pharmaceutical products from Pfizer in the US, in a move designed to strengthen and diversify its offering in the region.
The deal includes three of Pfizer’s injectable products and one inhaled solution.
The antibiotic injection clindamycin and inhaled acetylcysteine, which is used to prevent liver damage after paracetamol overdose, are already on the market. Acetylcysteine will continue to be marketed by Fresenius with Alvogen receiving profit sharing payments.
The agreement also gives the private US pharma two pending ANDA’s - the antifungal voriconazole and chemotherapy melphalan - both of which represent a generic market “with limited participation” and are scheduled for potential launch next year.
“These products will complement as well as significantly strengthen our existing portfolio, further enhancing our customer offering,” said chairman and chief executive Robert Wessman.
Pfizer is divesting the drugs under a precondition of closing its $17-billion purchase of Hospira, for which it received final regulatory approvals from the US and Brazil this week.